Table 1 Participant characteristics in development/calibration dataset (STATCOPE = Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD) and validation dataset (MACRO = Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease)
From: Serum bilirubin and the risk of chronic obstructive pulmonary disease exacerbations
STATCOPE (n = 853) | MACRO (n = 1018) | |
|---|---|---|
Age, years | 62 ± 8 | 66 ± 9 |
Male sex - no. (%) | 479 (56%) | 606 (60%) |
Race - no. (%) | ||
Black | 177 (21%) | 138 (14%) |
White | 651 (77%) | 830 (82%) |
Other | 20 (2%) | 50 (5%) |
BMI, kg/m2 | 27.2 ± 6.9 | 27.8 ± 6.2 |
Alcohol consumption, drinks per day | 0.48 ± 0.85 | 0.40 ± 1.03 |
Currently smoking - no. (%) | 257 (30%) | 222 (22%) |
Oxygen use - no. (%) | 408 (48%) | 604 (59%) |
ED visit or hospitalized for AECOPD in year prior to enrollment - no. (%) | 434 (51%) | 517 (51%) |
Steroids or antibiotics in previous year - no. (%) | 715 (84%) | 865 (85%) |
FEV1/FVC ratio, % | 44 ± 13 | 43 ± 13 |
Post-bronchodilator FEV1, L | 1.19 ± 0.57 | 1.12 ± 0.51 |
Post-bronchodilator FEV1, % predicted | 42 ± 18 | 40 ± 16 |
GOLD category - no. (%) | ||
1 | – | 1 (0.1%) |
2 | 278 (33%) | 277 (27%) |
3 | 293 (35%) | 410 (40%) |
4 | 277 (33%) | 327 (32%) |
Mean Serum Bilirubin (mg/dL) | ||
Enrollment/baseline | 0.65 ± 0.30 | 0.64 ± 0.29 |
Month 1 | – | 0.63 ± 0.28 |
Month 3 | – | 0.63 ± 0.28 |
Month 6 | 0.62 ± 0.28 | 0.63 ± 0.27 |
Month 9 | – | 0.63 ± 0.28 |
Month 12 | 0.65 ± 0.28 | 0.64 ± 0.28 |
Month 18 | 0.63 ± 0.27 | – |
Month 24 | 0.65 ± 0.28 | – |